| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT07556848) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2026-05-01 |
| A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors (NCT07466160) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2026-02-11 |
| First-in-human Study of 7MW4911 in GI Cancer (NCT07216560) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2026-01-13 |
| A Phase II Study of 9MW3811 in Patients With Pathological Scar (NCT07576608) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-12-29 |
| First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors (NCT07265622) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-11-12 |
| A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs (NCT06908928) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-08-11 |
| 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer (NCT07314723) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-08-01 |
| A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT07292714) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-07-15 |
| 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors (NCT06926998) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-04-15 |
| A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors (NCT06947226) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-04-01 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma (NCT06823427) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2025-01-17 |
| A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis (NCT06804590) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-11-16 |
| A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer (NCT06692166) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-09-10 |
| 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer (NCT06592326) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-08-22 |
| A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT06492005) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-07-26 |
| A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera (NCT06752746) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2024-03-21 |
| A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (NCT06196736) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-12-29 |
| 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer (NCT06079112) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-09-27 |
| A Study of 7MW3711 in Subjects With Advanced Solid Tumors (NCT06008379) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-08-28 |
| Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors (NCT05990452) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-08-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects (NCT05912049) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-07-26 |
| Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). (NCT06175351) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors (NCT05911984) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2023-06-30 |
| 6MW3511 in Patients With Advanced Solid Tumor (NCT05524194) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-10-01 |
| A Clinical Study of 6MW3211 in Patients With Renal Cancer (NCT05440045) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-09-01 |
| A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT05416749) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-08-05 |
| A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer (NCT05431569) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-07-10 |
| A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS (NCT05448599) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-07-08 |
| A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors (NCT05773937) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-06-21 |
| A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors (NCT05216965) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-06-11 |
| Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema (NCT05324774) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-02-28 |
| A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections (NCT05339802) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-02-16 |
| A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection (NCT05170243) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-01-21 |
| An Evaluation of 9MW1911 Injection in Healthy Subjects (NCT05803902) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-12-15 |
| A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm (NCT05048160) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-09-27 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD (NCT05297292) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-05-07 |
| A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection (NCT04784312) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-04-16 |
| Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema (NCT05324592) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2021-02-26 |
| A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19 (NCT04627584) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-12-29 |
| Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF (NCT04554056) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-09-21 |
| Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors (NCT04478461) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-09-03 |
| A Clinical Study to Evaluate MW33 Injection (NCT04533048) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-08-07 |
| Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (NCT04798313) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-06-02 |
| Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors (NCT04812509) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-03-20 |
| Efficacy and Safety of MW031 in PMO Subjects (NCT05215977) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2019-12-27 |
| Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (NCT04798326) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2019-06-25 |